Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 2104
- Registration Number
- NCT00014222
- Locations
- 🇺🇸
Sparks-Arkansas Oklahoma Cancer Treatment Centre, Fort Smith, Arkansas, United States
🇺🇸Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00006469
- Locations
- 🇺🇸
Washington Cancer Institute at Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center, Baltimore, Maryland, United States
Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 92
- Registration Number
- NCT00003612
- Locations
- 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸CentraCare Health Plaza, Saint Cloud, Minnesota, United States
🇺🇸Medcenter One Health System, Bismarck, North Dakota, United States
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 31
- Registration Number
- NCT00006227
- Locations
- 🇺🇸
Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00005051
- Locations
- 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸Saint Vincent Catholic Medical Center of New York, New York, New York, United States
🇺🇸New York Hospital Medical Center of Queens, Fresh Meadows, New York, United States
Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Radiation Therapy Oncology Group
- Registration Number
- NCT00009880
- Locations
- 🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Mount Carmel West Hospital, Columbus, Ohio, United States
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00028769
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Tulane University Health Sciences Center
- Registration Number
- NCT00028860
- Locations
- 🇺🇸
Tulane Cancer Center at Tulane University Hospital and Clinic, New Orleans, Louisiana, United States
Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 166
- Registration Number
- NCT00003128
- Locations
- 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸Tufts - New England Medical Center, Boston, Massachusetts, United States
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003342
- Locations
- 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.